Given recent findings linking IL-6-mediated STAT3 activation to NRF2 expression and signaling in cancer progression, particularly in pancreatic and oral SCC, we investigated whether CD109 regulates IL-6-mediated NRF2 expression and its downstream targets SOD1 and HO1 which are crucial anti-oxidative enzymes involved in cell survival and therapy resistance. Here, CD109 is linked to cancer.